{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:47:21Z","timestamp":1790380041169,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Science and Engineering: C"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.msec.2015.10.083","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T03:13:33Z","timestamp":1446520413000},"page":"748-753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Development of PLGA\u2013PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis"],"prefix":"10.1016","volume":"59","author":[{"given":"Rishikesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh Chandra","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.N.R.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan K.","family":"Topno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6365-7104","authenticated-orcid":false,"given":"Md Yousuf","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhuprava","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msec.2015.10.083_bb0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.pt.2006.09.004","article-title":"Leishmaniasis and poverty","volume":"22","author":"Alvar","year":"2006","journal-title":"Trends Parasitol."},{"issue":"4","key":"10.1016\/j.msec.2015.10.083_bb0010","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.msec.2015.10.083_bb0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1590\/S0037-86822011000500006","article-title":"Epidemiological aspects of human and canine visceral leishmaniasis in Montes Claros, State of Minas Gerais, Brazil, between 2007 And 2009","volume":"44","author":"Prado","year":"2011","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.msec.2015.10.083_bb0020","first-page":"238","article-title":"Immune response to leishmania infection","volume":"119","author":"Awasthi","year":"2004","journal-title":"Ind. J. Med. Res."},{"issue":"8","key":"10.1016\/j.msec.2015.10.083_bb0025","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.45.8.2185-2197.2001","article-title":"Clinical and experimental advances in treatment of visceral leishmaniasis","volume":"45","author":"Murray","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.msec.2015.10.083_bb0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4269\/ajtmh.1992.47.117","article-title":"Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease","volume":"47","author":"Grogl","year":"1992","journal-title":"Am.J.Trop. Med. Hyg."},{"issue":"2","key":"10.1016\/j.msec.2015.10.083_bb0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the new world","volume":"118","author":"Oliveira","year":"2011","journal-title":"Acta Trop."},{"key":"10.1016\/j.msec.2015.10.083_bb0040","first-page":"9","article-title":"Current treatment of leishmaniasis: a review","volume":"1","author":"Monzote","year":"2009","journal-title":"Open Antimicrob. Agents J."},{"issue":"3","key":"10.1016\/j.msec.2015.10.083_bb0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0035-9203(84)90131-7","article-title":"Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis)","volume":"78","author":"Thakur","year":"1984","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"6","key":"10.1016\/j.msec.2015.10.083_bb0050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/10611869808997874","article-title":"Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice","volume":"5","author":"Paul","year":"1998","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.msec.2015.10.083_bb0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/10408419709115139","article-title":"Leishmania phagolysosome: drug trafficking and protein sorting across the compartment","volume":"23","author":"Chakraborty","year":"1997","journal-title":"Crit. Rev. Microbiol."},{"issue":"Suppl. 1","key":"10.1016\/j.msec.2015.10.083_bb0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000048471","article-title":"Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion","volume":"45","author":"Berman","year":"1999","journal-title":"Chemotherapy"},{"issue":"8","key":"10.1016\/j.msec.2015.10.083_bb0065","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/nar\/gkn032","article-title":"Transforming growth factor-\u03b2-regulated miR-24 promotes skeletal muscle differentiation","volume":"36","author":"Sun","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.msec.2015.10.083_bb0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-5173(97)00417-1","article-title":"Amphotericin B toxicity and lethality: a tale of two channels","volume":"162","author":"Cohen","year":"1998","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.msec.2015.10.083_bb0075","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/CMR.9.4.512","article-title":"Carrier effects on biological activity of amphotericin B","volume":"9","author":"Brajtburg","year":"1996","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.msec.2015.10.083_bb0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/08982109309150728","article-title":"Mechanism of action of amphotericin B at the cellular level. Its modulation by delivery systems","volume":"3","author":"Bolard","year":"1993","journal-title":"J. Liposome Res."},{"issue":"12","key":"10.1016\/j.msec.2015.10.083_bb0085","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0165-6147(96)01012-7","article-title":"Amphotericin B: new life for an old drug","volume":"17","author":"Hartsel","year":"1996","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.msec.2015.10.083_bb0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"issue":"16","key":"10.1016\/j.msec.2015.10.083_bb0095","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(87)90543-0","article-title":"The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani","volume":"36","author":"Croft","year":"1987","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.msec.2015.10.083_bb0100","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.36.8.1630","article-title":"Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice","volume":"36","author":"Kuhlencord","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9143","key":"10.1016\/j.msec.2015.10.083_bb0105","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","article-title":"Trial of oral miltefosine for visceral leishmaniasis","volume":"352","author":"Sundar","year":"1998","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.msec.2015.10.083_bb0110","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","article-title":"Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis","volume":"341","author":"Jha","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msec.2015.10.083_bb0115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.biomaterials.2006.09.047","article-title":"Formulation of functionalized PLGA\u2013PEG nanoparticles for in vivo targeted drug delivery","volume":"28","author":"Cheng","year":"2007","journal-title":"Biomaterials"},{"issue":"0","key":"10.1016\/j.msec.2015.10.083_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10717544.2014.951746","article-title":"Study the effects of PLGA\u2013PEG encapsulated amphotericin B nanoparticle drug delivery system against Leishmania donovani","author":"Kumar","year":"2014","journal-title":"Drug Delivery"},{"issue":"2","key":"10.1016\/j.msec.2015.10.083_bb0125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/0974-777X.62883","article-title":"Treatment of visceral leishmaniasis","volume":"2","author":"Moore","year":"2010","journal-title":"J. Global Infect. Dis."},{"issue":"1","key":"10.1016\/j.msec.2015.10.083_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1021\/bc00031a015","article-title":"Mechanism of amide formation by carbodiimide for bioconjugation in aqueous media","volume":"6","author":"Nakajima","year":"1995","journal-title":"Bioconjug. Chem."},{"issue":"5","key":"10.1016\/j.msec.2015.10.083_bb0135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ijantimicag.2008.10.013","article-title":"N-(2-hydroxypropyl) methacrylamide\u2013amphotericin B (HPMA\u2013AmB) copolymer conjugates as antileishmanial agents","volume":"33","author":"Nicoletti","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"2","key":"10.1016\/j.msec.2015.10.083_bb0140","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jac\/dkn189","article-title":"Antileishmanial activity of nano-amphotericin B deoxycholate","volume":"62","author":"Manandhar","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.msec.2015.10.083_bb0145","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1128\/AAC.47.12.3774-3779.2003","article-title":"Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B","volume":"47","author":"Larabi","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.msec.2015.10.083_bb0150","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0378-5173(99)00434-2","article-title":"Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages","volume":"196","author":"Kayser","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.msec.2015.10.083_bb0155","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1007\/BF01644038","article-title":"Liposomes and nanoparticles as vehicles for antibiotics","volume":"19","author":"Kreuter","year":"1991","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.msec.2015.10.083_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future","volume":"47","author":"M\u00fcller","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.msec.2015.10.083_bb0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0169-409X(00)00120-4","article-title":"Mucoadhesive nanoparticulate systems for peptide drug delivery","volume":"47","author":"Takeuchi","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.msec.2015.10.083_bb0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2007.09.013","article-title":"Nano\/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives","volume":"125","author":"Mundargi","year":"2008","journal-title":"J. Control. Release"}],"container-title":["Materials Science and Engineering: C"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928493115305154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928493115305154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T02:25:08Z","timestamp":1567304708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928493115305154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":34,"alternative-id":["S0928493115305154"],"URL":"https:\/\/doi.org\/10.1016\/j.msec.2015.10.083","relation":{},"ISSN":["0928-4931"],"issn-type":[{"value":"0928-4931","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of PLGA\u2013PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Materials Science and Engineering: C","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msec.2015.10.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}